Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms 64-Cu-Dotatate, 64Cu-DOTA-tyr3-Octreotate, Copper Cu 64 dotatate + [4] |
Target |
Mechanism SSTR modulators(Somatostatin receptor modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (03 Sep 2020), |
RegulationOrphan Drug (EU), Fast Track (US), Priority Review (US) |
Molecular FormulaC65H87CuN14O19S2 |
InChIKeyIJRLLVFQGCCPPI-QMVMUTFZSA-K |
CAS Registry1426155-87-4 |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Start Date31 May 2024 |
Sponsor / Collaborator |
Start Date17 Jan 2023 |
Sponsor / Collaborator |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Neuroendocrine Tumors | US | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Somatostatin Receptor-Positive Neuroendocrine Tumor | Phase 1 | US | 23 Aug 2018 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 3 | 63 | rltoktpkii(anxgofopcm) = iomjmakigb uaulcaofxi (oxkrcnrueg, ptneogucir - srbatfjcxq) View more | - | 22 Dec 2022 | |||
Phase 3 | Somatostatinoma Somatostatin Receptor-Positive | 12 | (nzuvrankse) = lkvztumuli efszsmygoh (qreqaqmzlg ) View more | Positive | 01 Jun 2020 | ||
Not Applicable | - | rmjppaqyrh(zjwmurcxyt) = nflsnxevtx swifxybpzp (ghiqdzyfcf ) View more | - | 24 May 2016 | |||
rmjppaqyrh(zjwmurcxyt) = vpeohiagem swifxybpzp (ghiqdzyfcf ) View more |